ONT: Revenue up 12.3% CC, gross margin 62.2%, adjusted EBITDA loss halved to £22.1m

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

Oxford Nanopore Technologies' stock rose 6.6% after its interim results showed improved profitability, with gross margin expanding to 62.2% and adjusted EBITDA losses halving. The company also announced a new licensing deal expected to generate $20 million in fees. Berenberg maintained a Buy rating but lowered its price target to £2.00. The stock is still below its 52-week high of 215.6p.

Bank of America downgraded Onterris, Inc. to Underperform from Neutral and cut its price target to $18 from $31, according to the note cited in the article. The stock is shown trading around $15.24 at the time of publication, with the article referencing Onterris’ recent earnings call.

Onterris (NYSE:ONT) reported Q2 CY2026 revenue of $186.7 million, down 20.4% year on year, missing analysts’ estimates. The company’s full-year revenue guidance midpoint was $765 million, 10.9% below consensus. Non-GAAP EPS was $0.51, above estimates, and the stock fell 17.5% to $18.73 after results.

Onterris, Inc. (ONT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ont-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Onterris Reports Second Quarter Results, Updates Full-Year 2026 Guidance, and Announces Board-led Strategic Review Process Updates Date and Time of Conference Call to Today, Wednesday, August 5, at 5:30 p.m. Eastern Time Secon

PageGroup shares rose over 11% after it reported Q2 gross profit of £198m, down 0.2% year on year but ahead of analyst expectations, and said it sees signs of market normalisation. ME Group International gained about 11% after interim results showed flat £154m sales. Plus500 shares fell on weaker cash margin, and Oxford Nanopore dropped 12% after H1 sales missed expectations at £116.5m.